Drew Moghanaki

Drew Moghanaki: HORIZON-01 – ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib

Drew Moghanaki, Chief Medical Officer at Respirati, posted on X:

“Just when you thought the horizon for locally advanced NSCLC couldn’t get brighter… along comes HORIZON-01: ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib.
Thanks Millie Das for the heads up.”

Drew Moghanaki: HORIZON-01 - ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib

Other posts featuring Drew Moghanaki on OncoDaily.

ATS2025 cancer chemoradiotherapy Drew Moghanaki Millie Das NSCLC OncoDaily Oncology